1 / 23

GASTRIC CANCER

GASTRIC CANCER. GASTRIC CANCER. 4% 5 th position 2 nd cause of cancer related death in the world 5 y survival rate B:F=2:1 More frequent in Jap an, Latin America , Far East, North Europe. Incidence is droping. Pathology. Adenocarcinom a 90% Sarcom a Limfo ma. CAUSES.

navarra
Download Presentation

GASTRIC CANCER

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. GASTRIC CANCER

  2. GASTRIC CANCER • 4% 5th position • 2nd cause of cancer related death in the world • 5 y survival rate • B:F=2:1 • More frequent in Japan, Latin America, Far East, North Europe. • Incidence is droping

  3. Pathology • Adenocarcinoma 90% • Sarcoma • Limfoma

  4. CAUSES • 66-75% can be prevented with diet using high quantity of fruits and vegetables and low in salty foods. • Integral cereals and green teea can reduce the incidence • Vitamin C şi carotenoidsprobably decrease the risk • Alcoholmay increase the risk of GC in cardia region • Smoking increases the risk

  5. ETHIOLOGY • Atriphic gastritis • 9% will develop GC • Chronic inflammation – destruction of glands – lower capacity of acid secretion – intestinal metaplasia • Causes • Helicobacter pylori • Ac anti parietal cells – Biermer • Antral resection

  6. ETHIOLOGY • Helicobacter pylori • Distal GC + association with atrophy • Appears to be protective against procimal GC • 1/ 97 infectet patients develop CG • Inf:noninf=8:1, ONLY CERTAIN FENOTYPES

  7. ETHIOLOGY • Polyps • Hiperplastic – 80% • High risk over 0,5 cm • Adenomatos • Very high risck • Familial risk • 2-3X higher • Mutation in gene CHD1 -E-cadherina role in diferencietion and cel arhitecture • Molecular fenotype • c-met, K-sam involved in cell groth • p53 suppressor gene– 64% • cyclin E

  8. PATHOLOGY • Intestinal • Atrophy – metaplasia - displasia – adenoma - cancer • Difuz – linitis plastica • Submucosal invasion

  9. Macroscopic – Borrmann • Type I - polipoid well defined • Type II – polipoid with marked infiltration • Type III – ulceratio with infiltrated margins • Tip IV – linitis plastica • Microscopic – OMS • Adenocarcinoma – intestinal, difuse • Adenocarcinoma papilary • Adenocarcinoma tubular • Adenoacrcinom mucinos (>50% mucinous cells) • Signet cells carcinoma (>50% signet cells) • Adenosquamos carcinoma • Squamos cell carcinoma • Small cells carcinoma • Nondiferentiated • altele

  10. Primary tumor (T): Tis = carcinoma in situ: intraepithelial tumor without invasion of lamina propria T1 = tumor invades lamina propria or submucosa T2 = tumor invades muscularis propria or subserosa T3* = tumor penetrates serosa (visceral peritoneum) without invasion of adjacent structures T4**,*** = tumor invades adjacent structures *A tumor may penetrate the muscularis propria with extension into the gastrocolic or gastrohepatic ligaments or into the greater or lesser omentum without perforation of the visceral peritoneum. **Structures adjacent to the stomach include the spleen, transverse colon, liver, diaphragm, pancreas, abdominal wall, adrenal gland, kidney, small intestine, and retroperitoneum. ***Intramural extension to the duodenum or esophagus is classified by the depth of greatest invasion in any of these sites, including the stomach). Regional lymph nodes (N):Include the perigastric nodes along the lesser and greater curvatures, and the nodes along the left gastric, common hepatic, splenic, and celiac arteries. N0 = no regional lymph node metastasis N1 = metastasis to 1–6 regional lymph nodes N2 = metastasis in 7–15 regional lymph nodes N3 = metastasis in more than 15 regional lymph nodes Distant metastasis (M):M0 = no distant metastasis M1 = distant metastasis

  11. Grading • G1 - well diferentiated->95% glands • G2 – moderat diferentiated – 50-95% glands • G3 – poor diferentiated - <49% glands • Adc tubular – G1 • Adc signet cells – G3 • Adc small celss and non diferetiated – G4

  12. CLINICA PRESENTATION • Subjectiv • General neoplastic simptoms • Dispepsia • UGI bleeding • Objectiv • Tumor palpable • Hepatomegaly, ascites, jaundice, splenomagaly • Sister Mary Joseph – sign (umbilkical nodule) • Virchow sign – left supraclavicular LN • Krukenberg –ovarian MTS • Blumer – rectal palpable mass • Trousseau – migrating flebitis • Leser-Trelat – seborheic keratitis • Lab • Anemia • Ocult bleeding • ACE, CA 19.9

  13. Rx barium

  14. CT, MRI, echoendoscopy+biopsybrush citology, laparoscopy, lapro echography

  15. COMPLICATIONS • Bleeding • Perforation • Obstruction • Penetration

  16. TREATMENT • SURGICAL • Rezection • R0 – complete, no microscopic tumor left • R1 – microscopic tumor left in situ • R2 – macrosocopic residual tumor • Limfadenectomy • D1 – stations 1-6 • D2 – stations 7-11 • D3 – stations 12-14 • D4 – stations 15-16 • Omentectomy

  17. Endoscopic treatment Mucosal resection in early gastric cancer Paliative Sclerotherapy Laser destruction Stent

  18. TREATMENT • Chemotherapy • Neoadjuvant / adjuvant • 5-FU, doxorubicin şi mitomycin C (FAM) • Immunochemoterapy – CHT bound to specific tumoral ATB. Ag • Radioterapy • neoadjuvant • Chemoradiation • Adjuvant • Major discussions

More Related